TY - JOUR
T1 - Progression of
GBA1 severe and risk variants
T2 - a longitudinal mixed model analysis.
AU - Hanff, Anne-Marie
AU - McCrum, Christopher
AU - Rauschenberger, Armin
AU - Pachchek, Sinthuja
AU - Aguayo, Gloria A
AU - Pauly, Claire
AU - Jónsdóttir, Sonja R
AU - Tsurkalenko, Olena
AU - Pauly, Laure
AU - Landoulsi, Zied
AU - Leist, Anja K
AU - May, Patrick
AU - Zeegers, Maurice P
AU - Krüger, Rejko
N1 - Copyright © 2026 Hanff, McCrum, Rauschenberger, Pachchek, Aguayo, Pauly, Jónsdóttir, Tsurkalenko, Pauly, Landoulsi, Leist, May, Zeegers and Krüger.
PY - 2026/3/26
Y1 - 2026/3/26
N2 - INTRODUCTION: An association between severe
GBA1 variants and the progression of non-motor symptoms in PD has been reported, but the role of Parkinson's-risk (PD-risk)
GBA1 variants is less clear.
METHODS: We assessed symptom progression in individuals with severe and PD-risk variants compared to non-carriers. We analyzed longitudinal data from 726 individuals with typical PD, including 22 carriers of severe
GBA1 variants and 47 carriers of PD-risk
GBA1 variants.
RESULTS: The findings were not significant after adjusting for Bonferroni correction; however, linear mixed models analyses showed that at a nominal significance level of 5%, carriers of PD-risk or severe variants were associated with faster cognitive decline compared to non-carriers. Moreover, carriers of PD-risk variants were associated with faster worsening of apathy, quality of sleep, tremor, and non-motor symptoms [Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS I)] compared to non-carriers; however, we did not observe this tendency in individuals with severe variants.DISCUSSION: The exploratory study suggests associations between PD-risk variants and a more rapid disease progression among carriers compared to non-carriers. Nevertheless, the findings should be interpreted cautiously and require confirmation in an independent cohort before any reevaluation of their pathologic relevance.
AB - INTRODUCTION: An association between severe
GBA1 variants and the progression of non-motor symptoms in PD has been reported, but the role of Parkinson's-risk (PD-risk)
GBA1 variants is less clear.
METHODS: We assessed symptom progression in individuals with severe and PD-risk variants compared to non-carriers. We analyzed longitudinal data from 726 individuals with typical PD, including 22 carriers of severe
GBA1 variants and 47 carriers of PD-risk
GBA1 variants.
RESULTS: The findings were not significant after adjusting for Bonferroni correction; however, linear mixed models analyses showed that at a nominal significance level of 5%, carriers of PD-risk or severe variants were associated with faster cognitive decline compared to non-carriers. Moreover, carriers of PD-risk variants were associated with faster worsening of apathy, quality of sleep, tremor, and non-motor symptoms [Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS I)] compared to non-carriers; however, we did not observe this tendency in individuals with severe variants.DISCUSSION: The exploratory study suggests associations between PD-risk variants and a more rapid disease progression among carriers compared to non-carriers. Nevertheless, the findings should be interpreted cautiously and require confirmation in an independent cohort before any reevaluation of their pathologic relevance.
UR - https://pubmed.ncbi.nlm.nih.gov/41972104/
U2 - 10.3389/fnagi.2026.1771789
DO - 10.3389/fnagi.2026.1771789
M3 - Article
C2 - 41972104
SN - 1663-4365
VL - 18
JO - Frontiers in Aging Neuroscience
JF - Frontiers in Aging Neuroscience
M1 - 1771789
ER -